Non-alcoholic fatty liver disease surgery: Difference between revisions
Aditya Ganti (talk | contribs) No edit summary |
|||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Surgical intervention is not recommended for the management of non-alcoholic fatty liver disease. However, [[gastric bypass surgery]] is recommended in patients with non-alcoholic fatty liver disease and [[Body mass index|BMI]] greater than 40 who psychologically stable and failed medical therapy. | |||
==Surgery== | == Surgery == | ||
* | |||
==== Indications ==== | |||
* Patients with NAFLD and [[BMI]] greater than 40 who psychologically stable | |||
* In patients who failed medical therapy. | |||
* | |||
==== Surgical options ==== | |||
* The most common procedures are [[Adjustable gastric banding surgery|adjustable gastric banding]] and the [[Roux-en-Y|Roux-en-Y bypass]].<ref name="pmid2591798">{{cite journal |vauthors=Sukhanova NN |title=[Somatotypes in evaluating the physical development of 11-year-old schoolchildren] |language=Russian |journal=Gig Sanit |volume= |issue=9 |pages=84–6 |year=1989 |pmid=2591798 |doi= |url=}}</ref><ref name="pmid28507929">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref> | |||
* A Y-shaped section of the [[ileum]] is attached to the pouch so that [[food]] bypasses the [[duodenum]] and [[Jejunum|proximal section of the jejunum]]. | |||
* The size of the [[stomach]] is reduced either by stapling or [[Banding (medical)|banding]], creating a small pouch, assisting with [[weight loss]] by inducing | |||
** Earlier [[satiety]] | |||
** [[Calorie restriction|Reducing caloric intake]] | |||
** Decreasing absorptive capacity | |||
==== Complications ==== | |||
* Early complications include: | |||
** [[Peritonitis]] | |||
** [[Pulmonary embolism]] | |||
* Late complications include | |||
** [[Nutritional deficiencies]] | |||
** [[Iron deficiency anemia]] | |||
** [[Dumping syndrome]] | |||
** [[Ulcers]] | |||
==References== | ==References== |
Revision as of 15:16, 22 December 2017
Non-Alcoholic Fatty Liver Disease Microchapters |
Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases |
---|
Diagnosis |
Treatment |
Case studies |
Non-alcoholic fatty liver disease surgery On the Web |
American Roentgen Ray Society Images of Non-alcoholic fatty liver disease surgery |
Directions to Hospitals Treating Non-alcoholic fatty liver disease |
Risk calculators and risk factors for Non-alcoholic fatty liver disease surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Overview
Surgical intervention is not recommended for the management of non-alcoholic fatty liver disease. However, gastric bypass surgery is recommended in patients with non-alcoholic fatty liver disease and BMI greater than 40 who psychologically stable and failed medical therapy.
Surgery
Indications
- Patients with NAFLD and BMI greater than 40 who psychologically stable
- In patients who failed medical therapy.
Surgical options
- The most common procedures are adjustable gastric banding and the Roux-en-Y bypass.[1][2]
- A Y-shaped section of the ileum is attached to the pouch so that food bypasses the duodenum and proximal section of the jejunum.
- The size of the stomach is reduced either by stapling or banding, creating a small pouch, assisting with weight loss by inducing
- Earlier satiety
- Reducing caloric intake
- Decreasing absorptive capacity
Complications
- Early complications include:
- Late complications include
References
- ↑ Sukhanova NN (1989). "[Somatotypes in evaluating the physical development of 11-year-old schoolchildren]". Gig Sanit (in Russian) (9): 84–6. PMID 2591798.
- ↑ Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.